Published in Clin Vaccine Immunol on November 14, 2007
Measurement and quality control issues in multiplex protein assays: a case study. Clin Chem (2009) 2.11
Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem (2009) 1.95
An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis (2010) 1.70
Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev (2011) 1.60
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res (2013) 1.18
Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm (2014) 1.16
Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. J Immunol Methods (2011) 1.07
Accuracy and reproducibility of a multiplex immunoassay platform: a validation study. J Immunol Methods (2011) 1.05
Single molecule enzyme-linked immunosorbent assays: theoretical considerations. J Immunol Methods (2012) 1.01
Integrated review of the association of cytokines with fibromyalgia and fibromyalgia core symptoms. Biol Res Nurs (2009) 0.94
Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila) (2010) 0.93
Performance of multiplex cytokine assays in serum and saliva among community-dwelling postmenopausal women. PLoS One (2013) 0.88
Competitive electrochemiluminescence wash and no-wash immunoassays for detection of serum antibodies to smooth Brucella strains. Clin Vaccine Immunol (2009) 0.87
Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci (2010) 0.85
Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples. J Immunol Methods (2014) 0.84
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncol (2012) 0.83
Effect of pregnancy on serum cytokines in SLE patients. Arthritis Res Ther (2012) 0.81
Meso scale discovery and luminex comparative analysis of calbindin D28K. J Biomed Biotechnol (2009) 0.80
Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer (2010) 0.77
An ultrasensitive electrogenerated chemiluminescence-based immunoassay for specific detection of Zika virus. Sci Rep (2016) 0.76
Performance evaluation of FlowCytomix assays to quantify cytokines in patients with rheumatoid arthritis. Int J Clin Exp Med (2015) 0.75
A Multiplex Microsphere-Based Immunoassay Increases the Sensitivity of SIV-Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239. Biores Open Access (2013) 0.75
Proinflammatory cytokines. Chest (2000) 5.89
Multiplexed protein measurement: technologies and applications of protein and antibody arrays. Nat Rev Drug Discov (2006) 3.83
Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol (2003) 3.70
Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom (2004) 3.52
Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods (2006) 3.36
Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS (1998) 2.33
Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol (1999) 2.15
Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods (2005) 2.09
Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J Immunol Methods (2002) 2.04
Solid-phase and bead-based cytokine immunoassay: a comparison. Methods (2006) 1.87
High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA). Biotechniques (1999) 1.80
Multiplexed sandwich assays in microarray format. J Immunol Methods (2004) 1.60
Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer (2002) 1.47
Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant. J Immunol Methods (2006) 1.39
Heterophile antibody interference in a multiplexed fluorescent microsphere immunoassay for quantitation of cytokines in human serum. Clin Diagn Lab Immunol (2004) 1.36
The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods (2000) 1.34
Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis (2004) 1.28
Protein microarray platform for the multiplex analysis of biomarkers in human sera. J Immunol Methods (2006) 1.13
Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatants. J Immunol Methods (2004) 1.12
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 3.42
Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther (2002) 2.58
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 2.02
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One (2012) 1.70
Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol (2012) 1.69
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.37
Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol (2006) 1.21
Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther (2003) 1.07
Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol (2009) 1.06
Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol (2007) 1.02
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci (2009) 0.97
Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol (2011) 0.95
Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. J Clin Pharmacol (2009) 0.94
Molecular profiling and gene expression analysis in cutaneous sarcoidosis: the role of interleukin-12, interleukin-23, and the T-helper 17 pathway. J Am Acad Dermatol (2011) 0.94
Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. J Clin Pharmacol (2010) 0.93
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update. Ann N Y Acad Sci (2012) 0.91
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci (2011) 0.90
Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med (2013) 0.88
Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol (2010) 0.87
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther (2010) 0.87
The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatr Rheumatol Online J (2010) 0.85
Effects of 2 different anti-tumor necrosis factor-alpha agents in a primate model of subcutaneous abscess formation. J Infect Dis (2002) 0.82
Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal (2005) 0.81
IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum (2006) 0.78
Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol (2013) 0.77
Timing of High-Dose Rate Brachytherapy With External Beam Radiotherapy in Intermediate and High-Risk Localized Prostate CAncer (THEPCA) Patients and Its Effects on Toxicity and Quality of Life: Protocol of a Randomized Feasibility Trial. JMIR Res Protoc (2015) 0.75
Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med (2017) 0.75